CJC-1295 and Ipamorelin Peptide Protocols: What High-Performing Adults Should Know Before Getting Started
The question I hear most often from patients in their forties and fifties goes something like this: "My labs are fine, my training is dialed in, my sleep is decent. Why do I still feel a step slower than I did ten years ago?" A meaningful part of the answer sits inside the pituitary gland, and specifically in how it releases growth hormone as we age. CJC-1295 and ipamorelin are two peptides that have become common tools in that conversation. Before you start a protocol, here is what I think you should actually understand.
What These Peptides Do (and What They Don't)
CJC-1295 is a growth hormone-releasing hormone (GHRH) analog. Ipamorelin is a growth hormone secretagogue that mimics ghrelin at the GHSR receptor. Used together, they nudge your pituitary to release your own growth hormone in a pattern that resembles the natural pulses you had at 25. That is a meaningful distinction. You are not injecting growth hormone. You are prompting endogenous release, which preserves the feedback loops that keep the system safe.
Why pair them? The two peptides act on different receptors, and their effects are additive. CJC-1295 broadens and lengthens the pulse. Ipamorelin sharpens the amplitude. Ipamorelin is also relatively selective, meaning it does not meaningfully raise cortisol or prolactin at standard doses, which was a real problem with older secretagogues like GHRP-6.
What they do not do: replace testosterone, melt fat while you sit on the couch, or reverse a decade of poor sleep in a week. Patients who assume peptides are a shortcut around basic physiology tend to be disappointed. Patients who use them to accelerate work they are already doing tend to notice something real.
Who Tends to Be a Reasonable Candidate
In our practice, the adults who see the most value from CJC-1295 and ipamorelin usually share a few characteristics. They are typically 35 to 60. Their sleep quality has slipped. Recovery from training takes longer than it used to. Body composition has drifted toward more visceral fat even when weight on the scale is stable. IGF-1 levels sit in the lower third of the age-adjusted reference range.
Candidates I steer away from, or at least pause with, include anyone with an active or recent malignancy, uncontrolled diabetes, significant retinopathy, or pregnancy. Growth hormone signaling and cellular proliferation are linked, and while these peptides work through your own pituitary rather than exogenous GH, prudence matters. This is a conversation you have with a physician who knows your history, not something to order from a website.
What a Typical Protocol Looks Like
Most of our CJC-1295/ipamorelin protocols use a combined subcutaneous injection five nights per week, taken about 90 minutes after your last meal and shortly before bed. The empty stomach matters because circulating glucose and insulin blunt growth hormone release. Bedtime timing takes advantage of your natural nocturnal pulse.
Doses vary, but a common starting range is 100 mcg of ipamorelin with 100 mcg of CJC-1295 (without DAC) per injection. Some patients titrate up modestly over the first few months. Weekend breaks and periodic pauses (for example, five days on, two off, with a longer break every few months) help maintain pituitary responsiveness. Continuous, uninterrupted daily dosing at high amounts is where receptor desensitization becomes a real concern.
A note on the two versions of CJC-1295. The form with DAC (Drug Affinity Complex) has a half-life measured in days and produces a "bleed" of GHRH activity rather than clean pulses. The form without DAC has a half-life of about 30 minutes and pairs more physiologically with ipamorelin. In our clinic we generally use the non-DAC version for that reason.
What You Might Actually Notice, and When
Peptides are not stimulants. You do not feel them the way you feel caffeine or testosterone. The changes tend to layer in slowly.
- Weeks 1 to 4: Deeper sleep is usually the first thing patients report. Some notice more vivid dreams, which reflects more time in slow-wave and REM sleep.
- Weeks 4 to 12: Recovery from training improves. Joint stiffness in the morning often eases. Some patients report clearer skin.
- Months 3 to 6: Body composition shifts become measurable on a DEXA scan in patients who are also training and eating with intention. Waist circumference tends to move before scale weight does.
Side effects, when they occur, are usually mild and dose-related. Transient tingling in the hands, mild flushing after injection, occasional water retention early on, and rarely a headache. Injection site reactions are uncommon with a proper technique. If you notice persistent fluid retention, numbness, or changes in vision, that is a reason to pause and call your physician, not push through.
Labs Worth Tracking
Before starting, I want a baseline that includes IGF-1, IGFBP-3, fasting glucose and insulin, HbA1c, a lipid panel, comprehensive metabolic panel, and a full thyroid and sex hormone workup. Growth hormone signaling interacts with insulin sensitivity in both directions, so watching fasting glucose over time is not optional. IGF-1 should rise into the upper half of the age-adjusted range on therapy, not above it. When IGF-1 climbs too high, we lower the dose. The goal is a physiologic signal, not a supraphysiologic one.
Follow-up labs at 8 to 12 weeks, then every 6 months, give us the trend line. Trends matter more than any single value.
How These Peptides Fit Into a Broader Plan
I have never seen peptides work well in isolation. The patients who get the most from a CJC-1295/ipamorelin protocol are already sleeping seven to eight hours, resistance training two to four times per week, eating enough protein (usually 0.7 to 1.0 grams per pound of lean mass), and paying attention to alcohol. If any of those pillars is broken, fix that first. Peptides accelerate a good foundation. They do not build one.
These protocols also sit alongside other tools in a longevity-oriented plan: hormone optimization when indicated, targeted Weight Management support, cardiometabolic risk reduction, and structured strength work. A well-designed program considers all of them together rather than stacking interventions blindly.
Practical Questions to Ask Before You Start
- Where is the peptide sourced, and is it from a licensed U.S. compounding pharmacy?
- Who is monitoring my labs, and how often?
- What is the plan for cycling on and off?
- How does this protocol interact with any hormone optimization I am already on?
- What are the specific criteria that would tell us to stop?
If the answers to those questions are vague, that tells you something about the practice.
Peptide therapies discussed here are not FDA-approved and are offered pursuant to Fla. Stat. § 458.3245.
If you are considering whether a CJC-1295 and ipamorelin protocol makes sense for your goals, and you want a careful evaluation rather than a template, request a consultation with our team. We will look at your labs, your training, and your history, and tell you honestly whether this is the right next step.
Related from Hew Health